TORONTO, May 2 /CNW/ - ARIUS Research Inc. ("ARIUS") (TSX-V: ARI),
announced that Dr. David Young, Chairman, President and Chief Scientific
Officer will present an update on the company at the BioFinance conference in
Toronto. Dr. Young's presentation is scheduled for May 3, 2006 at 9:00 a.m.
EST at the Toronto Marriott Hotel.
About ARIUS Research
ARIUS Research Inc. is a biotechnology company dedicated to personalizing
cancer therapy through the discovery and development of novel anticancer
monoclonal antibodies (MAbs). Established in 1999, ARIUS has built a
proprietary technology platform, FunctionFIRST(TM), that rapidly identifies
powerful MAbs targeting a variety of cancer indications. This antibody
generation engine has enabled ARIUS to assemble a growing pipeline, which is
used for commercial collaborations and in-house development. ARIUS has ongoing
partnerships with key biotechnology and drug development companies. The
company is listed on the TSX Venture Exchange under the symbol "ARI".
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Forward-Looking Statement Certain statements in this news release
constitute "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, which involve known and unknown
risks, uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. Forward-looking statements in this
release include, but are not limited to, ARIUS successfully advancing its new
product programs as well as licensing opportunities. These statements are only
predictions and actual events or results may differ materially. Factors that
could cause such actual events or results expressed or implied by such forward-
looking statements to differ materially from any future results expressed or
implied by such statements include, but are not limited to: early stage of
development; technology and product development; dependence on and management
of current and future corporate collaborations; future capital needs;
uncertainty of additional funding; no assurance of market acceptance;
dependence on proprietary technology and uncertainty of patent protection;
intense competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.
%SEDAR: 00013708E
